Philipp Schmitt

Philipp Schmitt

Auto-generated profile, based on publicly available information

Philipp Schmitt

Research Volunteer, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2016 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
AGAndrew D. Gaudet
Andrew D. Gaudet
SMShweta Mandrekar-Colucci
Shweta Mandrekar-Colucci
JHJodie C.E. Hall
Jodie C.E. Hall
DSDavid R. Sweet
David R. Sweet
PSPhilipp J. Schmitt
Philipp J. Schmitt
PPPhillip G. Popovich
Phillip G. Popovich
Axon regeneration after spinal cord injury (SCI) fails due to neuron-intrinsic mechanisms and extracellular barriers including inflammation. microRNA (miR)-155–5p is a small, noncoding RNA that negatively regulates mRNA translation. In macrophages, miR-155-5p is induced by inflammatory stimuli and elicits a response that could be toxic after SCI. miR-155 may also independently alter expression of genes that regulate axon growth in neurons. Here, we hypothesized that miR-155 deletion would simultaneously improve axon growth and reduce neuroinflammation after SCI by acting on both neurons and macrophages. New data show that miR-155 deletion attenuates inflammatory signaling in macrophages, reduces macrophage-mediated neuron toxicity, and increases macrophage-elicited axon growth by ∼40% relative to control conditions. In addition, miR-155 deletion increases spontaneous axon growth from neurons; adult miR-155 KO dorsal root ganglion (DRG) neurons extend 44% longer neurites than WT neurons. In vivo, miR-155 deletion augments conditioning lesion-induced intraneuronal expression of SPRR1A, a regeneration-associated gene; ∼50% more injured KO DRG neurons expressed SPRR1A versus WT neurons. After dorsal column SCI, miR-155 KO mouse spinal cord has reduced neuroinflammation and increased peripheral conditioning-lesion-enhanced axon regeneration beyond the epicenter. Finally, in a model of spinal contusion injury, miR-155 deletion improves locomotor function at postinjury times corresponding with the arrival and maximal appearance of activated intraspinal macrophages. In miR-155 KO mice, improved locomotor function is associated with smaller contusion lesions and decreased accumulation of inflammatory macrophages. Collectively, these data indicate that miR-155 is a novel therapeutic target capable of simultaneously overcoming neuron-intrinsic and neuron-extrinsic barriers to repair after SCI. SIGNIFICANCE STATEMENT Axon regeneration after spinal cord injury (SCI) fails due to neuron-intrinsic mechanisms and extracellular barriers, including inflammation. Here, new data show that deleting microRNA-155 (miR-155) affects both mechanisms and improves repair and functional recovery after SCI. Macrophages lacking miR-155 have altered inflammatory capacity, which enhances neuron survival and axon growth of cocultured neurons. In addition, independent of macrophages, adult miR-155 KO neurons show enhanced spontaneous axon growth. Using either spinal cord dorsal column crush or contusion injury models, miR-155 deletion improves indices of repair and recovery. Therefore, miR-155 has a dual role in regulating spinal cord repair and may be a novel therapeutic target for SCI and other CNS pathologies.

24 October 2019 in Neuro-Oncology
Verified
Journal Article
Closed access
SBSuresh K Balasubramanian
Suresh K Balasubramanian
MSMayur Sharma
Mayur Sharma
VVVyshak A Venur
Vyshak A Venur
PSPhilipp Schmitt
Philipp Schmitt
RKRupesh Kotecha
Rupesh Kotecha
Manmeet S AhluwaliaManmeet S Ahluwalia
Manmeet S Ahluwalia
Background: The impact of activating alterations in non–small cell lung cancer (NSCLC) (epidermal growth factor receptor [EGFR] mutation/anaplastic lymphoma kinase [ALK] translocation) in prognosticating patients with brain metastasis (BM) is not well defined. This study was sought to identify this impact in NSCLC patients with BM accounting for the known validated variables. Methods: Among 1078 NSCLC-BM patients diagnosed/treated between January 1, 2000 and December 31, 2015, three hundred and forty-eight with known EGFR/ALK status were analyzed. Overall survival (OS) and intracranial progression-free survival (PFS) were measured from the time of BM. Results: Ninety-one patients had either ALK (n = 23) alterations or EGFR (n = 68) mutation and 257 were wild type (WT; negative actionable mutations/alterations). Median age of EGFR/ALK+ NSCLC BM patients was 60 years (range 29.8–82.6 y) and ~50% (n = 44) had Karnofsky performance status (KPS) score >80. Median number of BM was 2 (1 to ≥99). The median OS for the ALK/EGFR+ NSCLC BM was 19.9 versus 10.1 months for the WT (P = 0.028). The number of BM in the EGFR/ALK+ group did not impact OS (BM = 1 with 21.1 months vs 2–3 with 19.1 months and >3 with 23.7 months, P = 0.74), whereas fewer BM in the WT cohort had significantly better OS (BM = 1 with 13.8 mo, 2–3 with 11.0 mo and >3 with 8.1 mo; P = 0.006) with the adjustment of age, KPS, symptoms from BM and synchronicity. Conclusions: Number of BM does not impact outcomes in the EGFR/ALK+ NSCLC patients, implying that targeted therapy along with surgery and/or radiation may improve OS irrespective of the number of BM. Number of BM, extracranial metastasis (ECM), and KPS independently affected OS/PFS in WT NSCLC BM, which was consistent with the known literature.

18 November 2016 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SBSuresh K. Balasubramanian
Suresh K. Balasubramanian
MSMayur Sharma
Mayur Sharma
DSDanilo Silva
Danilo Silva
VKVidhya Karivedu
Vidhya Karivedu
PSPhilipp Schmitt
Philipp Schmitt
SCSamuel T. Chao
Samuel T. Chao

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SBSuresh Kumar Balasubramanian
Suresh Kumar Balasubramanian
PSPhilipp Schmitt
Philipp Schmitt
MSMeena Sadaps
Meena Sadaps
VKVidhya Karivedu
Vidhya Karivedu
DKDebra Kangisser
Debra Kangisser
DPDavid M. Peereboom
David M. Peereboom
E13516 Background: Primary central nervous system lymphoma (PCNSL), a form of extranodal non-Hodgkin lymphoma represents 3% of primary CNS tumors. It is aggressive but typically confined to the CNS. Despite improvements in the management of PCNSL, more than 50% of patients eventually relapse. There are limited data on PCNSL from larger cohort studies. Methods: With IRB approval, the Cleveland Clinic Neuro-Oncology Center database was used to identify patients treated between 2006-2015 for PCNSL. Overall survival (OS) from the diagnosis of PCNSL and progression free survival (PFS) were the primary and secondary end points respectively. Cox proportional hazards models were used for data analysis. Results: 86 PCNSL patients were included in the analysis. Only 5% (4/76) were HIV positive. The median age of diagnosis was 63 (range 15 - 86) and 50% were males. 88% of patients presented only with brain lesion, 8% only in eye and 4% had both brain and eye involvement. 15% of patients (12/81) had positive CSF findings. Treatment included: chemotherapy (CT) alone (39% of patients); chemoimmunotherapy (CIT) (32%); CIT with radiotherapy (RT) (13%); RT alone (11%); CT with RT (4%); and immunotherapy (IT) alone (1%). Among 23 patients (31%) who received RT upfront, 74% had WBRT (n = 17). The most common upfront therapy was high dose methotrexate (HD MTX) (44%), followed by HD MTX with rituximab (23%), RTOG 0227 (12%), RTOG 1114 (11%) and rest 14% included rituximab or temozolomide or other cytotoxic chemotherapy alone or in combinations. The most common relapse site was brain (72%), followed by eyes (12%) and spine (8%). The median follow-up was 26 months. At last follow up, 41% had died and 93% of which were PCNSL-related. The median PFS and OS were 17.7 months and 84 months, respectively. There was a trend towards superior PFS in upfront IT vs. no IT (20 vs. 14 months, p 0.08). Better performance status (KPS > 80 vs. < 80, HR 0.42 (p = 0.033)) and PFS ≥ 24 months compared to ≤ 24 months (p = 0.0012) were associated with improved OS. Conclusions: We report a large single institution cohort of PCNSL patients treated in the era of immunotherapy. In our cohort, better KPS (≥80) and PFS ≥ 24 months had improved OS. Upfront IT showed a trend towards improved PFS.

1 November 2016 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SBSuresh Kumar Balasubramanian
Suresh Kumar Balasubramanian
PSPhilipp Schmitt
Philipp Schmitt
SCSamuel Chao
Samuel Chao
LALilyana Angelov
Lilyana Angelov
AMAlireza Mohamaddi
Alireza Mohamaddi
MAManmeet Ahluwalia
Manmeet Ahluwalia
BACKGROUND:NSCLC is the most common cause of BM. Activating mutation in EGFR and ALK constitutes 15% and 5% of NSCLC respectively. The Graded Prognostic Assessment (GPA) scale in NSCLCBM doesn’t include activating mutation that is associated with better prognosis. We report the impact of mutations on survival at our tertiary care center.METHODS:With IRB approval, Cleveland Clinic Brain Tumor Center’s database was queried for NSCLCBM with known mutational status (2000-2015). The primary endpoint was OS from diagnosis of NSCLCBM. Cox proportional hazards models were used for data analysis. Stepwise variable selection was used to identify independent prognostic factors.RESULTS:348 patients (23 ALK+, 68 EGFR+, 257 wild-type) with median age of 60 years (range 30-93) were included for analysis. KPS was >80 in 143 patients (44%), 70-80 in 144 (44%) and 3 BM in 99 (29%) patients. Initial therapy included whole brain radiation (WBRT) +/- Surgery in 164 (47%), stereotactic radiosurgery (SRS) +/- Surgery in 128 (37%), WBRT + SRS in 31 (9%), other treatments were employed in 18 patients (5%). 50% of mutation positive patients received adjuvant targeted therapy. Median OS for ALK and EGFR+ NSCLCBM was 19.9 months vs. 10.1 months in wild-type (p .003). On multivariate analysis, KPS, activating mutation, extracranial metastases (ECM) to bone, lymph nodes and adrenal gland were independent predictors of OS in contrast to conventional GPA. Revised GPA based on KPS, mutational status and presence of ECM was developed with three groups: “unfavorable” (median OS = 3.9 months), “intermediate” (median OS = 12.3 months) and “favorable” (median OS = 24.3 months) (p < .001). CONCLUSIONS:A revised DS-GPA for NSCLCBM that includes KPS, mutational status and ECM is proposed.